Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2018

View Archived Issues

Atridia begins phase I study of SHR-0410 in healthy volunteers

New phase I trial studies GD2-specific CAR and IL-15 expressing NKTs in neuroblastoma

Bionomics initiates phase II study of BNC-210 for the treatment of agitation in elderly

Discovery of novel inhibitor of human NMT for treatment of the common cold

First patient enrolled in SARA-INT study of Sarconeos in sarcopenia

Lilly initiates phase II study of LY-3303560 in early symptomatic AD

Lupin submits MAA to the EMA for etanercept biosimilar

Fluorescent imaging with a myelin-binding probe shows promise

PCI Biotech Holding, IMV enter research collaboration

Janssen Pharmaceutica patents new PDE2A inhibitors

Oncolytics Biotech and the Keck School of Medicine collaborate to study new Reolysin combination

Japanese approval for Opdivo with Yervoy in unresectable melanoma

Roche and Genentech disclose IRAK-4 inhibitors

Beactica extends master service agreement with Sanofi

Croma-Pharma identifies H2S-releasing compounds

Janssen to terminate studies of daratumumab with atezolizumab and JNJ-63723283

Pfizer's Xeljanz approved for new indication in Japan

Janssen Pharmaceutica discloses BACE1 and/or BACE2 inhibitors

Braeburn resubmits CAM-2038 NDA for opioid use disorder to FDA

Roche presents compounds for HBV infection

New phase I study evaluates MRX-2843 in patients with advanced or metastatic solid tumors

MedImmune initiates phase I study of MEDI-2228 in relapsed or refractory multiple myeloma

Symphogen opens enrollment in phase I study of Sym-023 in advanced solid tumors or lymphomas

Mepolizumab approved for EGPA in Japan

Polysialic acid levels tied to prostate cancer aggressiveness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...